Carisma Therapeutics Inc Revenue Growth Rates (CARM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Carisma Therapeutics Inc   (NASDAQ: CARM)
 

CARM's Revenue Growth by Quarter and Year

Carisma Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CARM Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September 45.25
2nd Quarter June 0.00
1st Quarter March 3.73
FY 48.98

CARMs Annual Revenue
Carisma Therapeutics Inc 's Revenue in the fiscal year 2024 $ 19.63 millions
Carisma Therapeutics Inc 's Revenue in the fiscal year 2023 $ 14.92 millions
Carisma Therapeutics Inc 's Revenue in the fiscal year 2022 $ 40.00 millions
Carisma Therapeutics Inc 's Revenue in the fiscal year 2021 $ 26.54 millions
Carisma Therapeutics Inc 's Revenue in the fiscal year 2020 $ 11.24 millions




CARM Revenue third quarter 2025 Y/Y Growth Comment
Carisma Therapeutics Inc achieved in the third quarter 2025, above Company average Revenue surge of 1234.81% year on year, to $ 45.25 millions.

Looking into third quarter 2025 results within Major Pharmaceutical Preparations industry 97 other companies have achieved higher Revenue growth. While Carisma Therapeutics Inc ' s Revenue doubling of 1234.81% ranks overall at the positon no. 1849 in the third quarter 2025.


CARM Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - -16.28 % - -
3rd Quarter September 1234.81 % -11.49 % - -
2nd Quarter June - 158.43 % 31.85 % 21.08 %
1st Quarter March 9.71 % 4.94 % 295.12 % -80.97 %
FY   - 31.21 % 324.15 % -

Financial Statements
Carisma Therapeutics Inc 's third quarter 2025 Revenue $ 45.25 millions CARM's Income Statement
Carisma Therapeutics Inc 's third quarter 2024 Revenue $ 3.39 millions Quarterly CARM's Income Statement


CARM Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 6.19 % 12.27 % -
3rd Quarter September - -63.15 % 7.58 % -
2nd Quarter June - 170.59 % 9.88 % 229.27 %
1st Quarter March 3.61 % -20.93 % - -95.9 %
FY (Year on Year)   - 31.21 % 324.15 % -


Back to CARM Growth rate Comparisons >> Back to CARM Growth rate Comparisons >>


Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #98
Healthcare Sector #288
Overall #1849

Revenue Y/Y Growth Statistics
High Average Low
3552.63 % 328.25 % -80.54 %
(Sep 30 2016)   (Sep. 30, 2015)
Revenue third quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #98
Healthcare Sector #288
Overall #1849
Revenue Y/Y Growth Statistics
High Average Low
3552.63 % 328.25 % -80.54 %
(Sep 30 2016)   (Sep. 30, 2015)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Carisma Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CARM's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CARM's III. Quarter Q/Q Revenue Comment


Carisma Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 19.91 $ 19.58 $ 20.28
Y / Y Revenue Growth (TTM) - - 32 % 31.14 % -59.95 %
Year on Year Revenue Growth Overall Ranking # 2526 # 2909 # 2714 # 3195 # 3421
Seqeuential Revenue Change (TTM) - - 1.7 % -3.45 % -2.13 %
Seq. Revenue Growth (TTM) Overall Ranking # 1849 # 153 # 1654 # 3214 # 3443


Cumulative Revenue growth Comment
Carisma Therapeutics Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2025, compare to Revenue of $ 20 millions a year ago.

In the Healthcare sector 394 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2526, from total ranking in previous quarter at 2909.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 98
Healthcare Sector # 395
Overall # 2526

Revenue TTM Y/Y Growth Statistics
High Average Low
3552.63 %
 328.25 %
-80.54 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 98
Sector # 288
S&P 500 # 1849
Cumulative Revenue growth Comment
Carisma Therapeutics Inc realized trailing twelve months of $ 0 millions, in the Sep 30 2025, compare to Revenue of $ 20 millions a year ago.

In the Healthcare sector 394 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2526, from total ranking in previous quarter at 2909.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 98
Healthcare Sector # 395
Overall # 2526

Revenue TTM Y/Y Growth Statistics
High Average Low
3552.63 %
328.25 %
-80.54 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 98
Sector # 288
S&P 500 # 1849




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CARM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue doubling for the quarter ending Sep 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2025
Ataibeckley Inc 1,772.50%$ 1,772.500 millions
Ars Pharmaceuticals Inc 1,471.62%$ 1,471.615 millions
Vaxart Inc 1,367.93%$ 1,367.930 millions
Solana Company1,266.67%$ 1,266.667 millions
Carisma Therapeutics Inc 1,236.78%$ 1,236.780 millions
Liquidia Corporation1,121.72%$ 1,121.718 millions
Cormedix Inc 810.22%$ 810.215 millions
Scienture Holdings Inc 809.71%$ 809.715 millions
Astrotech Corp773.53%$ 773.529 millions
Xilio Therapeutics Inc 742.51%$ 742.510 millions
Applied Therapeutics Inc 719.67%$ 719.672 millions
Lexicon Pharmaceuticals Inc 710.40%$ 710.400 millions
Bio Green Med Solution Inc 710.00%$ 710.000 millions


About Carisma Therapeutics Inc Revenue Growth Rates (CARM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Carisma Therapeutics Inc (CIK 1485003).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-25-110444
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Carisma Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.